This result signifies that the patient has two copies of a normal function allele. Based on the genotype result this patient is predicted to be an normal metabolizer of CYP2C19 substrates. There is no reason to selectively adjust the dose of most medications that are metabolized by CYP2C19. Please consult a clinical pharmacist for more information about how CYP2C19 metabolic status influences drug selection and dosing.